Cargando…
A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
BACKGROUND: We explored the therapeutic effects of dinaciclib, a cyclin-dependent kinase (CDK) inhibitor, in the treatment of thyroid cancer. MATERIALS AND METHODS: Seven cell lines originating from three pathologic types of thyroid cancer (papillary, follicular and anaplastic) were studied. The cyt...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312924/ https://www.ncbi.nlm.nih.gov/pubmed/28207834 http://dx.doi.org/10.1371/journal.pone.0172315 |